Objective: The purpose of this meta-analysis of longitudinal studies is to determine the safety and efficacy of artesunate combined with other forms of adjunctive therapies for severe malaria.Methods: Following the PRISMA guidelines, we searched multiple databases with the search terms “artesunate” and “adjunctive therapy” and “severe malaria” in July 2020. If the search showed a randomized controlled trial, the study was included in this meta-analysis. The random-effects model was used to calculate the combined incidence rate and relative risk or risk difference.Results: This meta-analysis included nine longitudinal studies with 724 participants. We found that the mortality rates in the artesunate monotherapy group and the artesunate + adjuvant therapy group are similar (RD = −0.02, 95% confidence interval: −0.06–0.02). The incidence of adverse reactions in the artesunate monotherapy group and the artesunate + adjuvant therapy group was also similar.Conclusion: No significant differences in safety and efficacy were observed between the artesunate monotherapy group and the artesunate + adjuvant therapy group. Higher quality and rigorously designed randomized controlled studies are needed to validate our findings.
resistance is of a great concern, additional RCTs with high-quality and more rigorous design are warranted to substantiate the efficacy and safety in different populations and epidemiological regions.
The past decades has shown that cerebral malaria has a high mortality rate and patients may suffer further neurological sequelae even after treatment with drugs. Artesunate, an internationally recognized antimalarial...
As the kinetics of novel coronavirus pneumonia (COVID-19) outbreak still going all over the world and we can't predict when it'll make that turnaround and start coming down, seeking ways to prevent and control this disease is particularly important. Here we describe the role of traditional Chinese medicine in preventing COVID-19. In this clinical observation study, we selected 65 people who came back from Hubei province as subjects and launched a mass drug administration with them. We collected the data of the days from Hubei, non-symptoms rate, temperature before and after administration of these people. We treated them by isolating for 14 days and taking Deng's Herbal Tea Granula once a day for seven days. Then we assessed the possible efficacy of Deng's Herbal Tea Granula on COVID-19. Enrolled people had an average age of 27 years old (3–66 years old), among which 34 (53.97%) were females, with a median temperature of 36.4℃ (36.1–36.8℃). The median of the days from Hubei was 16 days (10–27 days). None of them presents any abnormal clinical manifestation. Isolation is the most effective way to defend and control COVID-19, but accompanied by the treatment of Deng's Herbal Tea Granula may increase the power of prevention. Not only this plant solid beverage which made of Chinese medicine can keep the temperature of all the suspected people at a healthy and stable level, but also is suitable for a large group of ages.
Background Malaria is a major public health problem in Togo. Guangzhou University of Chinese medicine of China, and the Ministry of Health and Social Security of Togo launched a nationwide artemisinin compound Mass Drug Administration Project in East Mono with a population of 150,000. Before launching the project, the sensitivity test of artemisinin piperaquine tablet was conducted in Elawagnon general clinic. On this background, we evaluated the efficacy and safety of artemisinin piperaquine in the treatment of uncomplicated falciparum malaria in children under five years of age. Methods In this study, children aged 6-59 months without complications of falciparum malaria were observed, and the selected cases were treated with artemisinin piperaquine. The patients were followed up for 28 days to observe the fever clearance time, parasitemia, gametophyte, cure rate, haemoglobin and msp-2 gene polymorphism. The primary end point was the 28-day cure rate, and PCR corrected reinfection and recrudescence. This research was conducted according to standardized WHO protocol for the assessment of the efficacy of anti-malarial treatment. Results A total of 91 children participated in the study. The adequate clinical and parasitological response (ACPR) before PCR-corrected were 66 (72.52%) and 90 (98.90%) after PCR-corrected. The patient was well tolerated to artemisinin piperaquine and no serious adverse reactions were observed. The average hemoglobin level increased by 0.05g/dl per day (p< 0.0001). The gametophyte doesn’t declined at the beginning of treatment, however, 14 days later, it dropped(D21:p<0. 05; D28: p< 0. 01). In the msp-2 gene polymorphism study of 24 children with positive parasite after treatment, 1 case of msp-2 with 3D7 haplotype and FC27 haplotype was reported, indicating that it’s recrudescence, with a frequency of 4.2% (1/24); The others maybe reinfection, with a frequency of 95.8% (23/24). Conclusion Artemisinin piperaquine was effective in treating uncomplicated falciparum malaria in children under 5 years of age in Togo and well tolerated. Plasmodium falciparum in Togo remains sensitive to artemisinin piperaquine, which could be used as a trial drug in the region. Trial Registration Trial registration: ECGPHCM No. B2017-054-01; MHSST AVIS N° 0001/2016/CBRS du 07 janvier 2016. Registered 17 March 2014, http://www.chinadrugtrials.org.cn/eap/main
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.